EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern?

Paloma Dias da Cruz, Betânia Rodrigues Santos, Poli Mara Spritzer iD

PLOS One · 14.05.2025 · 20 (5) · e0323606

DOI: 10.1371/journal.pone.0323606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 14.05.2025. Verfasst von Paloma Dias da Cruz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul (RS), Brazi…. Hauptthemen laut MEDLINE: Transgender Persons, Hemostasis, Gender-Affirming Procedures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transgender women have an increased incidence of venous thromboembolism (VTE) compared with cisgender individuals. However, data on hemostatic parameters in this population are scarce. We aimed to evaluate hemostatic parameters in transgender women receiving gender-affirming hormone therapy (GAHT) compared with cisgender controls. We conducted a cross-sectional study including 40 transgender women (sample size based on prior calculation), and age- and body mass index-matched cisgender women (n = 25) and cisgender men (n = 25) as controls. Blood samples were collected between 2016 and 2023. We assessed hemostatic parameters (plasminogen activator inhibitor-1 [PAI-1], free protein S, vascular cell adhesion molecule-1, antithrombin, anticoagulant protein C, prothrombin time activity, thrombin time), hormonal profile (estradiol, sex hormone-binding globulin, estrogen dose, total testosterone, and free androgen index), and inflammatory markers (fibrinogen, C-reactive protein, and leukocyte count). Transgender women (mean [SD] age, 30.6 [8.0] years; median GAHT duration, 36.5 months) and cisgender women had similar hemostatic and inflammatory parameters. Compared with cisgender men, transgender women had higher PAI-1 levels (p = 0.001) and lower free protein S levels (p = 0.023). No differences were found in other hemostatic parameters between the groups. In conclusion, transgender women on long-term GAHT had higher levels of PAI-1 and lower levels of free protein S than cisgender men, indicating a slightly more prothrombotic profile. However, their hemostatic and inflammatory parameters were similar to those of cisgender women, suggesting a shift towards a female pattern. Factors beyond GAHT may contribute to the increased risk of VTE in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsHemostasisGender-Affirming ProceduresHumansFemaleAdultMaleCross-Sectional StudiesPlasminogen Activator Inhibitor 1Venous ThromboembolismYoung AdultEstrogens

Substanzen

Plasminogen Activator Inhibitor 1Estrogens

Autor:innen und Institutionen

  • Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul (RS), Brazil.
  • Post-Graduate Program in Endocrinology, Medicine School, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
  • Department of Physiology and Post-Graduate Program in Physiology, UFRGS, Porto Alegre, RS, Brazil.

ORCID-Profile: Poli Mara Spritzer

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul

Zitieren

APA

da Cruz, P. D., Santos, B. R., & Spritzer, P. M. (2025). Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern?. PLOS One, 20(5), e0323606. https://doi.org/10.1371/journal.pone.0323606

Vancouver

da Cruz PD, Santos BR, Spritzer PM. Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern?. PLOS One. 2025;20(5):e0323606. doi:10.1371/journal.pone.0323606

BibTeX
@article{daCruz2025,
  author = {da Cruz, Paloma Dias and Santos, Betânia Rodrigues and Spritzer, Poli Mara},
  title = {Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern?},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {5},
  pages = {e0323606},
  doi = {10.1371/journal.pone.0323606}
}
Kostenlos starten →